

State of the **SCHOOL** Address

Dean John J. Reilly, Jr., MD
University of Colorado School of Medicine



School of Medicine

UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS

January 10, 2024

A vertical photograph on the left side of the slide shows a campus scene with green trees, a paved path, and a sign that reads "The Blue Birch Gateway Battered Person's Shelter".

2024 State of the School Address

AGENDA

- New Leadership Recruits
- Faculty Recognition
- Report Card: *How Did We Perform on Goals From Last Year?*
- Snapshot of the Current State of the School
- Upcoming Challenges: *A Look Ahead.*
- Anschutz Acceleration Initiative Awardees

New Leadership Appointments



Yuri Agrawal, MD, MPH
Otolaryngology,
Head & Neck Surgery



Ihab Kamel, MD, PhD
Radiology



Maryam Asgari, MD, MPH
Dermatology

New Leadership Appointments



Jerica Berge, PhD, MPH
ACCORDS



Aimee Gardner, PhD
Associate Dean of
Faculty Development



David DiGregorio, PhD
Physiology & Biophysics

Distinguished Professors



Sean Colgan, PhD
Medicine



Frank deGruy, MD
Family Medicine

Goals for 2023: Progress a Year Later



**Focus on Faculty
Well-being &
Engagement**



**Quality & Safety
With Our Clinical
Partners**



**Prepare for
LCME
Reaccreditation**



**Lease, Renovate Clinic
Space for Anschutz
Wellness Center**

Departmental Action from 2022 Survey



ORGANIZATIONAL CULTURE

- Recognition & appreciation
- Equity
- Transparent communication
- Work life integration

WORK OPTIMIZATION

- Email reduction
- In-basket
- Mini pilot grants
- Scheduling
- Check-out specialist
- Unanticipated event algorithm
- Innovation thinktank

FACULTY & LEADERSHIP DEVELOPMENT

- Faculty development
- Leadership pipeline
- Coaching
- Mentoring

CONNECTION & COLLEGIALITY

- Book club
- Peer support
- DOM@Table
- Social events

Funded Departmental Well-being Leaders Launched (~ 20 New Initiatives)

Action From CU SOM 2022 Survey



ORGANIZATIONAL CULTURE

- Changes to paid parental leave
- New faculty recognition programs
- New processes to manage allegations of unprofessional conduct



WORK OPTIMIZATION

- Prioritized initiatives to redesign clinical systems that highlight the importance of protected time for non-face-to-face patient care & inform pilot programs to align work to modern practice demands



FACULTY & LEADERSHIP DEVELOPMENT

- New leader onboarding
- New mid-career leadership program
- Refresh of the Academy of Medical Educators
- Pilot of web-based coaching for faculty
- Support for the Mentoring Academy



REDUCE CLERICAL WORK

- Launch of initiatives to re-examine annual reviews & promotion dossiers
- Improve travel approval processes
- Reduce e-mail burden



ADVOCACY

- CMS
- Verbal orders in ambulatory settings
- Telehealth



Aimee Gardner, PhD

Associate Dean of
Faculty Development

Faculty Development

Support Career Progression

- Academy of Medical Educators


Leadership Development

- Leader Onboarding
- THRIVEForward

Mentoring

- Taskforce (Niranjan Manoharan)

All Faculty Survey Timeline



Faculty & Resident/Fellow Survey

**CLINICIAN &
RESIDENT / FELLOW**



**SCIENTIST &
NON-CLINICAL
FACULTY**



Goals for 2023: Progress a Year Later



**Focus on Faculty
Well-being &
Engagement**



**Quality & Safety
With Our Clinical
Partners**



**Prepare for
LCME
Reaccreditation**



**Lease, Renovate Clinic
Space for Anschutz
Wellness Center**

Quality & Safety With Our Partners

- Quality Incentive Program with UCHealth
 - Substantial improvement in most of the measures that we can influence
 - Mortality most notable
- Significant Improvement in Key Variables at CHCO



Goals for 2023: Progress a Year Later



**Focus on Faculty
Well-being &
Engagement**



**Quality & Safety
With Our Clinical
Partners**



**Prepare for
LCME
Reaccreditation**



**Lease, Renovate Clinic
Space for Anschutz
Wellness Center**

Reaccreditation



- Report Due This Fall
- Site Visit March 2025
- Likely Areas of Focus
 - New curriculum
 - Branch campus at CSU
- 13 Working Groups on Schedule
- Effort Led by Bonnie Kaplan, MD

Goals for 2023: Progress a Year Later



**Focus on Faculty
Well-being &
Engagement**



**Quality & Safety
With Our Clinical
Partners**



**Prepare for
LCME
Reaccreditation**



**Lease, Renovate Clinic
Space for Anschutz
Wellness Center**

Clinic Space for Anschutz Wellness Center



Kelet Robinson, MD
Medical Director

- Finalizing Lease Agreement With Planned Opening in Spring 2024
- Hired Kelet Robinson, MD, as Medical Director Effective 2/1/2024

Longer Term Goals from 2023



**With Our Partners,
Create & Sustain High
Reliability Programs of
Clinical Excellence**



**Develop the
Personalized Medicine
Program to Have
Meaningful & Growing
Impact on Patient Care
Delivery**



**Move Faculty
Research Discoveries
Into Clinical Care**


A vertical image on the left side of the slide shows a campus scene with green trees, a paved path, and a building with orange circular architectural features. A sign is visible on a tree.

Multidisciplinary Cancer Clinics

1 Patient Visit, >4 Disciplines, >20 Providers Review Each Case

- Thoracic
 - Breast
 - Endocrine
 - Sarcoma
 - Gastrointestinal
 - Head & Neck
 - Genitourinary
 - Brain
- ▶ Seen by **1-5 Providers in One Day**
 - ▶ Collective Experience of **Thousands of Cases**
 - ▶ Expert **Radiology & Pathology Reviews**
 - ▶ **Supportive Care Services** Provided
 - ▶ Wait Time is **One Week**
 - ▶ Outside Care Plan **Altered >30% of the Time**
 - ▶ Providers Often Lead **Cutting-edge Clinical Trials**

Multidisciplinary Cancer Clinics



Clinical Results

Survival Rates 2023 - Stages 1-4 | % of Patient Living More Than 5 Years

Cancer Types (All Stages)	Metro Denver (UCCC)		Colorado	National
	Volume	Relative Survival Rate	Relative Survival Rate	Relative Survival Rate- All Stages
Prostate	1,921	98.8%	90.1%	97%
Breast	2,319	95.4%	94.5%	91%
Non-Hodgkin's Lymphoma	849	81.0%	73.9%	74%
Rectal	441	77.0%	75.4%	68%
Liver	695	41.1%	20.1%	21%
Lung	1,579	46.3%	26.1%	23%
Pancreatic	934	26.7%	12.8%	12%

5-Year Survival Rates for Stage IV Patients

Improved Survival Across 11 Cancer Types

UC Cancer Center		SEER	UC Cancer Center Survival Rates % of SEER Rates
Cancer Type (All Stages)	Survival Rate	Survival Rate	
Prostate	63%	32%	197%
Breast	45%	30%	150%
Lung	16%	7%	229%
Melanoma	45%	32%	141%
Thyroid	81%	53%	153%
Liver	15%	3%	500%
Pancreatic	11%	3%	367%
Kidney & Renal	30%	15%	200%
Colorectal	31%	14%	221%
Corpus Uteri	29%	18%	161%
Lymphoma*	73%	67%	109%

*Non-Hodgkin's Lymphoma

Recognitions & Awards

- **QOPI** (Quality Oncology Practice Initiative) **Certified**
- **ASCO/COA Patient-Centered Cancer Care Certification**



ASCO[®] AMERICAN SOCIETY OF
CLINICAL ONCOLOGY

- Faculty Set **International National Treatment Guidelines**
(~50 Committees)
- **Benchmarking** via 33 Member Institutions



- **INCP** (Integrated Network Cancer Program) Member



- **Radiation Oncology Program of Excellence**



- **FACT** Accredited (Foundation for the Accreditation of Cellular Therapy)
for Bone Marrow Transplant & Immune Effector Cells
- **Kaiser & Optum Program** of Excellence for Bone Marrow Transplant
- **Aetna** Institute of Excellence for Bone Marrow Transplant



Longer Term Goals from 2023



**With Our Partners,
Create & Sustain High
Reliability Programs of
Clinical Excellence**



**Develop the
Personalized Medicine
Program to Have
Meaningful & Growing
Impact on Patient Care
Delivery**



**Move Faculty
Research Discoveries
Into Clinical Care**

A vertical strip on the left side of the slide shows a campus scene with green trees, a paved path, and a sign that reads "The Elmer Berch Gateway Battered Person's Shelter".

By the Numbers

238,000+
patients consented

97,539
genotyped

39,393
with return of results

31
drugs in Pharmacogenomics Panel

**GI Oncology
Pharmacogenomics
Pilot**

Personalized Medicine

CYP2C19 *1/*17

Rapid metabolizer.

- The patient is a rapid metabolizer of **Clopidogrel**. The US Food and Administration suggests label-recommended dosage and administration of **Clopidogrel**. The CPIC Dosing Guidelines report risk of increased platelet reactivity and decreased residual platelet aggregation. Ultrarapid metabolizers are associated with an increased risk of bleeding complications.

CES1 rs71647871 C/C (WT)

- Consider label recommended dosage of **Clopidogrel** if no contraindications.

CYP1A2 rs762551 A/A (HOM)

- Patient may have decreased on-treatment platelet reactivity when treated with **clopidogrel** as compared to patients with the wild-type genotype.

ABCB1 rs1045642 A/G (HET)

- People with this genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction or stroke) when treated with **clopidogrel** in people with acute coronary syndrome or myocardial infarction as compared to people with homozygous GG genotype. Contradictory findings have been reported in the literature.

CYP3A4 rs2242480 C/C (WT)

Extensive (normal) metabolizer.

- Consider label recommended dosage of **Clopidogrel** if no contraindications.

BestPractice Advisory - Chtgst, Amc Burn Icu

Attention (1)

Warning: CLOPIDOGREL CYP2C19-ALTERED METABOLIZER (BPA#2841)

Lab Results

Component	Value	Date/Time
CYP2C19INT	Intermediate Metabolizer - *2/*17	08/21/2018 01:40 PM

Genetic testing shows this patient may have inadequate antiplatelet response from clopidogrel and is at significant risk for stent thrombosis and major adverse cardiovascular events following stent placement.

Recommendation: Consider prasugrel or ticagrelor if no contraindication.

See [CPIC guidelines](#) or page Pharmacogenomic Consult at 303-266-4510



Remove the following orders?

Remove

Keep

clopidogrel (PLAVIX) tablet 75 mg
75 mg, Oral, Starting Today at 0814

Apply the following?

Order

Do Not Order

ticagrelor (BRILINTA) tablet

Order

Do Not Order

prasugrel (EFFIENT) tablet

Acknowledge Reason


Contraindicated

Cost Concern


Other

✓ Accept

Patient Impact: GI Oncology Pilot



Patient Impact



Longer Term Goals from 2023



**With Our Partners,
Create & Sustain High
Reliability Programs of
Clinical Excellence**



**Develop the
Personalized Medicine
Program to Have
Meaningful & Growing
Impact on Patient Care
Delivery**



**Move Faculty
Research Discoveries
Into Clinical Care**

Gates Institute



Terry Fry, MD
Inaugural Director

- A State-of-the-Art Facility Translating Laboratory Discoveries into Regenerative, Cellular & Gene Therapies for Patients
- Launched with Terry Fry, MD, as Inaugural Director

Early Phase Clinical Trials - Adult

Adult CD19 CAR-T & Adult CD19X22 CAR-T Trials

UCD19

Phase I Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission

CD19x22

Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)

A vertical image on the left side of the slide shows a park scene with green trees, a paved path, and a sign that reads "The Elmer Berch Gateway Rattler Paved's Shelter".

Early Phase Clinical Trials - Pediatric

Pediatric CD19 CAR-T & Pediatric CD19X22 CAR-T Trials

UCD19

Phase I/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)

CD19x22

Phase I Dose Escalation and Preliminary Efficacy Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Early Phase Clinical Trials



[Home](#) > [News](#) > CU Ophthalmologists Administer Novel Treatment for Single Patient Facing Rare Genetic Condition

CU Ophthalmologists Administer Novel Treatment for Single Patient Facing Rare Genetic Condition

Fewer than 20 patients have been diagnosed with posterior column ataxia with retinitis pigmentosa (PCARP) in the last 50 years. When Grace Hoyt became one of them, Department of Ophthalmology faculty members sought out a treatment solution.

Snapshot 2023



**We Are Big &
We Continue
to Grow**



**Partnerships
With the
Community**

A vertical strip on the left side of the slide shows a campus scene with green trees, a paved path, and a sign that reads "The Elmer Smith Gateway Battered Person's Shelter".

We Are Big & We Continue to Grow

533
new faculty
in 2023

4521
employed by
CU SOM

2973
volunteer
clinical faculty

982
employed by
affiliates

TABLE 1 Faculty and Student Comparisons
University of Colorado School of Medicine
Benchmarked against All Medical Schools

Percentile	Students	Faculty						
	Medical Students	Total Full-Time (FT) Faculty ¹	Tot. FT Fac. FY 2021-FY 2022 % Change	Tot. FT Fac. FY 2017-FY 2022 CAGR ²	Basic Science FT Faculty	Percent Basic Sci. FT Faculty	Clinical FT Faculty	Percent Clinical FT Faculty
		4,992			293		4,699	
90	869	2,767	8.7%	6.6%	255	27.5%	2,471	94.6%
				5.9%				94.1%
80	776	1,928	4.7%	5.2%	197	18.6%	1,741	92.7%
	754							
70	733	1,495	3.2%	3.8%	166	15.5%	1,386	91.5%
			2.9%					
60	676	1,269	2.3%	3.3%	137	12.4%	1,115	90.0%
50	613	1,004	1.3%	2.6%	101	11.0%	895	89.0%
40	528	820	0.0%	1.4%	80	10.0%	740	87.6%
30	493	639	(0.7%)	0.7%	64	8.5%	562	84.5%
20	436	376	(3.2%)	(1.3%)	50	7.3%	326	81.4%
						5.9%		
10	331	182	(9.1%)	(3.9%)	37	5.4%	132	72.5%
Mean	621	1,305	0.1%	2.9%	129	14.6%	1,176	85.4%
Valid N	144	144	144	143	144	144	144	144

CU SOM vs. All Medical Schools (Faculty & Students)



Revenue Comparisons

University of Colorado School of Medicine
Benchmarked against Public Medical Schools

Percentile	Reported Measures & Trends												
	Total Revenue	Tot. Rev. FY 2021- FY 2022 % Change	Tot. Rev. FY 2022 CAGR¹	Practice Plan Revenue	Prac. Plan Rev. FY 2021- FY 2022 % Change	Prac. Plan Rev. FY 2017- FY 2022 CAGR²	Hospital Support³	Total Federal Research Grants and Contracts	Other Grants and Contracts	Government and Parent Support	Gift and Endowment Revenue	Tuition & Fees Revenue	Misc. Revenue
	\$2,426,356,533			\$969,841,927			\$522,125,611	\$407,305,732	\$202,132,159		\$100,255,800		\$146,495,174
90	\$1,955,085,249	13.5%	9.9%	\$734,963,918	21.6%	12.2%	\$518,789,005	\$306,101,404	\$151,879,403	\$130,638,014	\$64,483,336	\$50,756,426	\$119,264,269
			8.3%			8.3%						\$50,460,921	
80	\$1,518,105,454	11.4%	7.9%	\$602,985,659	15.4%	8.2%	\$304,349,067	\$208,905,865	\$110,333,957	\$103,066,062	\$35,024,111	\$40,794,680	\$73,934,132
		10.6%			12.7%								
70	\$1,023,358,361	10.1%	7.2%	\$441,477,724	11.4%	7.5%	\$247,495,872	\$138,846,308	\$80,231,216	\$83,602,433	\$20,468,473	\$37,123,752	\$28,560,772
60	\$844,120,429	8.3%	6.3%	\$330,263,833	9.0%	6.4%	\$198,055,601	\$94,454,388	\$53,186,759	\$69,314,380	\$16,869,114	\$32,728,360	\$13,615,370
50	\$623,887,310	7.1%	5.7%	\$266,479,899	6.7%	6.0%	\$140,578,691	\$67,095,220	\$40,647,000	\$55,319,482	\$8,883,287	\$29,736,032	\$10,249,214
40	\$490,975,837	5.2%	5.2%	\$167,904,125	4.9%	4.7%	\$103,476,861	\$42,093,693	\$29,139,667	\$42,456,533	\$4,718,463	\$23,955,937	\$7,776,175
30	\$328,899,532	3.7%	4.3%	\$128,180,918	3.1%	4.1%	\$68,996,869	\$17,479,087	\$17,224,093	\$35,813,734	\$3,188,945	\$20,755,331	\$4,061,530
20	\$240,308,203	2.4%	3.1%	\$56,347,250	1.2%	2.7%	\$32,227,972	\$10,343,590	\$9,455,266	\$28,454,888	\$2,509,834	\$14,915,198	\$2,338,589
										\$27,739,210			
10	\$109,128,154	(1.5%)	1.4%	\$15,219,637	(4.0%)	(2.6%)	\$10,686,789	\$7,967,833	\$4,439,951	\$17,623,337	\$1,486,413	\$11,154,229	\$630,878
Mean	\$902,266,199	8.1%	5.9%	\$357,761,916	7.6%	5.2%	\$205,612,470	\$128,832,780	\$72,669,848	\$69,491,643	\$24,699,080	\$29,657,129	\$41,679,910
Valid N	89	89	89	82	81	79	89	89	89	89	89	89	89

CU SOM vs Public Medical Schools (Revenue)

Percentile	Grants and Contracts (G&C)						Derived Measures of Total Revenue							
	Total G&C	Federal Research G&C (Direct)	Federal Research G&C (Indirect)	Indirect Rate for Organized Research ¹	Other G&C (Direct)	Other G&C (Indirect)	% Practice Plan	% Hospital Support	% Federal Research Grants and Contracts	% Other Grants and Contracts	% Government and Parent Support	% Gifts and Endowment	% Tuition and Fees	% Misc.
	\$609,437,891	\$295,406,216	\$111,899,516		\$177,298,132	\$24,834,027								
90	\$449,063,748	\$219,698,015	\$89,285,702	60.6%	\$131,727,899	\$22,432,445	51.7%	36.3%	19.3%	16.1%	30.2%	4.2%	15.1%	11.1%
												4.1%		6.0%
80	\$311,759,962	\$150,560,750	\$62,796,122	57.7%	\$96,818,881	\$15,616,175	46.3%	29.9%	16.8%	9.7%	23.9%	3.2%	9.3%	5.4%
70	\$206,942,199	\$100,073,479	\$38,027,965	56.3%	\$72,835,730	\$9,389,514	41.9%	27.4%	14.5%	8.7%	16.5%	2.7%	5.8%	4.0%
							40.0%			8.3%				
60	\$154,841,341	\$67,930,361	\$24,622,962	55.5%	\$43,978,623	\$6,399,930	38.5%	25.2%	13.5%	7.8%	11.4%	2.0%	4.7%	2.9%
50	\$115,931,600	\$43,828,029	\$19,996,057	54.5%	\$36,089,680	\$4,300,953	35.2%	22.4%	11.7%	6.2%	9.2%	1.8%	4.3%	2.0%
								21.5%						
40	\$68,329,825	\$26,363,705	\$10,749,873	53.5%	\$28,164,176	\$2,158,134	34.1%	18.8%	9.4%	5.5%	6.9%	1.6%	3.4%	1.3%
30	\$39,976,836	\$13,770,376	\$4,383,551	52.0%	\$15,231,421	\$1,115,451	28.9%	15.6%	6.7%	4.3%	5.6%	1.2%	2.9%	1.1%
20	\$22,543,887	\$7,490,623	\$2,966,145	49.8%	\$8,628,728	\$689,887	22.1%	12.7%	4.4%	3.3%	4.2%	0.8%	2.3%	0.6%
													2.1%	
10	\$14,127,970	\$5,495,530	\$1,679,410	47.5%	\$4,289,887	\$452,442	7.6%	7.8%	2.8%	2.4%	2.0%	0.6%	1.8%	0.4%
											1.1%			
Mean	\$201,502,628	\$92,473,470	\$36,359,310	53.8%	\$62,857,910	\$9,811,939	33.6%	22.8%	11.5%	7.5%	13.7%	2.2%	6.6%	4.7%
Valid N	89	89	89	89	89	89	82	89	89	89	89	89	89	89

Snapshot 2023



**We Are Big &
We Continue
to Grow**



**Partnerships
With the
Community**

A photograph of a campus scene. In the foreground, a large tree with green leaves is partially visible. The sun is shining through the leaves, creating a starburst effect. In the background, there is a large orange sculpture with circular openings. A signpost with multiple signs is visible, including one for 'The Blue Breach Gateway Battered Person's Shelter' and another for 'University of Colorado Anschutz Medical Campus'.

Traverse Academy

Partnership with Cherry Creek Schools



67

schools

53K

students

90%

graduation
rate

150+

languages
spoken

52%

students of
color (48%
white)

30%

free &
reduced
lunch

Cherry Creek School District Snapshot

Traverse Academy



- Partnership with CU Department of Psychiatry & Cherry Creek School District
- CU Provides 6 Clinicians (Psychologists & LCSWs) & Clinical Director
- Intensive Outpatient Program Model
- Full Schedule of Educational Offerings Designed Around Therapeutic Need



Aurora Public Schools

Blue Birch
Gateway Battered
Person's Shelter
Aurora, Colorado
University of Colorado
Anschutz Medical Campus

University of Colorado
Anschutz Medical Campus

University of Colorado
Anschutz Medical Campus

Partnership w/ Aurora Public Schools

- We (AWC) Are Part of the ABC Collective
 - Young Improvements, which is the nonprofit arm of Driven By Our Ambitions
 - Apprentice of Peace Youth Organization Young Aspiring Americans for Social & Political Activism (YAASPA)
- Negotiating With APS for the Repurposing of the Paris School Into a Community Center
- Goal is to Address Aspects of the Social Determinants of Health






Serving the Community


Partnership with HCPF

Colorado Patient Growth

**Total Unique Medicaid Members
Served by CUSOM Providers**



Total CUSOM Medicaid Visits



UPL Program Growth

ADULT AMBULATORY SPECIALTY CARE

Total Unique Members Served
FY'18: **32,387** FY'22: **66,041**



INCREASED 104%

Total Member Specialty Care Visits
FY'18: **202,081** FY'22: **386,940**



INCREASED 91%



Health First Colorado Members experience **like wait times** for Specialty appointments compared to all payor data



Members with CUSOM as their medical home **secured accelerated access** to Specialty Care via enhanced navigational support

Programs Supported By UPL Funds

- Six Building Blocks + Behavioral Health
- Aurora Wellness Network: Medical Legal Partnership
- WORTH (Wellness Opportunity, Resiliency

- Colorado Pediatric Psychiatry Consultation & Access Program Rural Project
- ECHO
- Adolescent Medicine

- Statewide Facilitation of Care for Sickle Cell Disease & Other Hemoglobinopathies in Colorado
- Colorado Hospitals Substance Use and

Total Investment in Programs to Date: \$189.2M

- Team)
- Expanding Access to Mental Health Treatment for Refugees & Traumatized Immigrant Populations

- Aurora Wellness Network: Just Keep Breathing
- Delivering Specialty Neurological & Psychiatric Care to Medicaid Population With Functional Neurological Disorders (FND)

- Collaborative
- Post-Discharge Telehealth Nursing Visits for Medically Complex Children at High Risk for Readmission

Upcoming Challenges



A Look Ahead



Challenge 1

Improving professional satisfaction while meeting an unceasing demand for clinical services



Challenge 2

Continuing to improve quality & safety in collaboration with our hospital partners




Challenge 3

The potential for a rise in the uninsured population in Colorado with the expiration of the public health emergency



Change in Medicaid Enrollment - Colorado



Disenrolled

344.3K

Coverage Renewed

381.1K

Terminate for Procedural Reasons Determined Ineligible Coverage Renewed Pending



<https://www.kff.org/report-section/medicaid-enrollment-and-unwinding-tracker-overview/>

Eligibility Redetermination

Summary

- Please Fill Out the Faculty Survey!
- We Continue to Attract Outstanding Talent
- We Are a Unique Resource in the State
- We Continue to Grow at 8+% CAGR
 - Despite that, access for patients remains a struggle



Anschutz Acceleration Initiative **AWARDEES**



Anschutz Acceleration Initiative
AWARDEES



Maryam Asgari, MD, MPH
Professor & Chair, Dermatology
CU School of Medicine

Project:
*Implementation of
Personalized Skin Cancer
Screening: Using Genetic
& Clinical Risk Factors to
Identify a High-Risk
Subgroup*

Anschutz Acceleration Initiative
AWARDEES



Valeria Canto-Soler, PhD
Associate Professor, Ophthalmology
CU School of Medicine

Project:
*Retinal Transplant to
Restore Vision in Patients
with Macular Degeneration*

Anschutz Acceleration Initiative
AWARDEES



Eduardo Davila, PhD

Professor, Medical Oncology
CU School of Medicine

Project:
*MyD88 Platform for
Enhancing Cellular
Cancer Immunotherapy*

Anschutz Acceleration Initiative
AWARDEES



Steven Edmundowicz, MD

Professor, Gastroenterology
CU School of Medicine

Project:
*Transforming
Gastrointestinal Cancer
Care from Inpatient
Surgery to Outpatient
Endoscopy by Enabling
Third Space Endoscopy*

Anschutz Acceleration Initiative
AWARDEES



Joaquin Espinosa, PhD

Professor, Pharmacology
CU School of Medicine

Project:
*Immunomodulatory
Therapy for Down
Syndrome*

Anschutz Acceleration Initiative
AWARDEES



Antonio Jimeno, MD, PhD

Professor, Medical Oncology
CU School of Medicine

Project:
*Targeting Protein
Translation Elongation to
Treat Cancer Patients*

Anschutz Acceleration Initiative
AWARDEES



Jayashree Kalpathy-Cramer, PhD

Professor, Ophthalmology
CU School of Medicine

Project:
*Oculomics as a
Biomarker for
Comprehensive & Non-
Invasive Patient Health
Assessment*

Anschutz Acceleration Initiative
AWARDEES



Dan Matlock, MD

Professor, Geriatrics
CU School of Medicine

Project:
*Making Personalization
the Standard Through
Rapid Design,
Implementation, Testing
& Maintenance*

Anschutz Acceleration Initiative
AWARDEES



Jeffrey Stansbury, PhD
Senior Associate Dean for Research,
Craniofacial Biology
CU School of Dental Medicine

Project:
*Multi-material 3D Print
Processing of
Antimicrobial &
Antifungal Dental
Prosthetics*



THANK YOU!